Date: 10 March, 2023
Time: 14:00 CET
The WHO R&D Blueprint organized a consultation with the MARVAC partners and focal points from at-risk countries to discuss Marburg vaccine and therapeutic candidates and integrating research during an outbreak.
Agenda
1- Outbreak sit rep including diagnostics and epidemiology
2- Review of core trial protocols for vaccines and therapeutics
3- Panel discussion from at-risk country focal points
PRESENTATIONS
Current epidemiological situation of the outbreak in Equatorial Guinea and outbreak response
Marburg reference laboratory Lab procedures and results from Equatorial Guinea
Session 1. Review of evidence and prioritization of candidate vaccines
Candidate vaccines developers’ update:
- ChAd3-MARV Program Update (Sabin Vaccine Institute)
- VSV-MARV Program (IAVI)
- Live, Attenuated Recombinant Vesicular Stomatitis (rVSV) Vectored Vaccine (Public Health Vaccines)
- rVSVN4CT1-AMARV GP1 Vaccine (Emergent BioSolutions/Auro Vaccines)
- ChAdOx1 Marburg vaccine (University of Oxford)
WHO Expert Group on vaccines prioritization update
Session 2. Access to investigational vaccines already in internationally transferable vials
Ongoing efforts to fund investigational vaccines already in internationally transferable vials.
Session 3. Towards agreed trial platforms and simple protocols for vaccine studies
Session 4. Towards agreed trial platforms and simple protocols for therapeutics studies?
Candidate therapeutics developers’ update:
Towards a pan-filovirus therapeutics protocol - Potential designs and proposed next steps